TriangleCabozantinib 80 MG (NCT05931393)
Cabozantinib 80 MG trial for RCC (NCT05931393). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced, unresectable or metastatic kidney cancer that progressed on or after cabozantinib alone. They must have received it for at least six months and tolerated 60 milligrams daily.
The idea: increase oral cabozantinib to 80 milligrams daily. It blocks signals involved in tumor growth and blood-vessel formation. Researchers assess how long disease stays controlled and monitor safety. Biopsies are optional for a small subgroup.
This phase 2 study plans 18 patients. Tian Zhang leads at UT Southwestern in Dallas, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.